CANTREAT develops a nanotechnology-based chemotherapy treatment that precisely targets high-risk tumors while minimizing systemic side effects associated with traditional chemotherapy. By utilizing already approved cytostatics in a targeted manner, CANTREAT aims to enhance treatment efficacy and improve patient outcomes in difficult-to-operate cases.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional chemotherapy often lacks precise targeting, leading to systemic side effects as the cytotoxic drugs affect both cancerous and healthy cells. This lack of specificity limits the dosage and effectiveness of the treatment, especially in difficult-to-operate tumors, and significantly impacts the patient's quality of life.
Solution
CANTREAT is developing a nanotechnology-based drug delivery system designed to enhance the precision of chemotherapy. The system encapsulates approved cytostatic drugs within nanoparticles that are engineered to selectively target high-risk tumor cells. This targeted approach aims to maximize the drug's impact on the tumor while minimizing exposure to healthy tissues, thereby reducing the severe side effects associated with conventional chemotherapy. By improving the therapeutic index of existing drugs, CANTREAT seeks to offer more effective treatment options, particularly for tumors that are hard to reach or surgically remove.
Target Audience
The primary target audience includes oncologists and hospitals seeking to improve chemotherapy outcomes and reduce side effects in patients with difficult-to-treat cancers.
Features
- Nanoparticle encapsulation of approved cytostatic drugs for targeted delivery
- Selective targeting of tumor cells to minimize off-target effects
- Enhanced drug penetration and retention within the tumor microenvironment
- Reduced systemic toxicity compared to traditional chemotherapy regimens
- Compatibility with a range of existing chemotherapeutic agents